Therapeutic approaches in Parkinson's disease and related disorders
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The lack of effective therapies for neurodegenerative disorders is one of the most relevant challenges of this century, considering that, as the global population ages, the incidence of these type of diseases is quickly on the rise. Among these disorders, synucleinopathies, which are characterized by the abnormal accumulation and spreading of the synaptic protein alpha‐synuclein in the brain, already constitute the second leading cause of parkinsonism and dementia in the elderly population. Disorders with alpha‐synuclein accumulation include Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Numerous therapeutic alternatives for synucleinopathies are being tested in pre‐clinical models and in the clinic; however, only palliative treatments addressing the dopaminergic deficits are approved to date, and no disease‐modifying options are available yet. In this article, we provide a brief overview of therapeutic approaches currently being explored for synucleinopathies, and suggest possible explanations to the clinical trials outcomes. Finally, we propose that a deeper understanding of the pathophysiology of synucleinopathies, together with a combination of therapies tailored to each disease stage, may lead to better therapeutic outcomes in synucleinopathy patients. image Synucleinopathies, neurodegenerative disorders characterized by the abnormal accumulation of the protein alpha‐synuclein, constitute the second leading cause of parkinsonism and dementia in the elderly population, however, no disease‐modifying options are available yet. In this review, we summarize the therapeutic approaches currently being explored for synucleinopathies, suggest possible explanations to the clinical outcomes, and propose areas of further therapeutic improvement. This article is part of a special issue on Parkinson disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485
Self-citationIwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A., Kittel, A., & Saitoh, T. (1995) · Neuron · doi:10.1016/0896-6273(95)90302-x · Cited by 1,316 · cited 2×
“Alpha-synuclein is a synaptic protein involved in synaptic transmission and vesicle release (U eda et al. 1993; Iwai et al. 1994; George et al. 1995; Fortin et al. 2005) that pathologically aggregates within neurons and glial cells in the form of Lewy bodies, neuronal cytoplasmic inclusions, and glial cytoplasmic incl…”
BackgroundSelf-citationCurcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254 · cited 2×
“2014), anti-aggregation compounds (Ono et al. 2004; Caruana et al. 2011; Wobst et al. 2015), autophagy enhancers (Renna et al.”
BackgroundPapp, M. I., Kahn, J. E., & Lantos, P. L. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90219-0 · Cited by 991
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
Prion-like mechanisms in neurodegenerative diseases
Frost, B., & Diamond, M. I. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2786 · Cited by 776
α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Wakabayashi, K., Yoshimoto, M., Tsuji, S., & Takahashi, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00407-8 · Cited by 643
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607
Self-citation
Cited by
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629
“For cases in which the aggregation-prone protein or protein fragment is intrinsically disordered, stabilization of the stable state is more challenging, and many rational design efforts have focused on inhibition of the process of aggregation itself (231, 232).”
BackgroundGPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease
Guan, J., Yang, B., Fan, Y., & Zhang, J. (2017) · Neuroimmunomodulation · doi:10.1159/000478908 · Cited by 53
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191648 · Cited by 46
“Cellular processes considered to be valid targets for drug development include the molecular processes leading to -synuclein accumulation (synthesis, aggregation and clearance), as well as mitochondrial dysfunction and neuroinflammation [14].”
BackgroundTitze-de-Almeida, R., Titze-de-Almeida, S. S., Ferreira, N. R., Fontanari, C., Faccioli, L. H., & Del Bel, E. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00043-9 · Cited by 18
Metadata
- Authors
- Valera, E., & Masliah, E.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-02-10
- Volume
- 139
- Issue
- S1
- Pages
- 346-352
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2226926731
- Cited by
- 52
- References
- 19
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.